Drug Profile
Injectable MPL allergy vaccine - Allergy Therapeutics
Alternative Names: Birch pollen allergen extract; Birch pollen modified allergen tyrosine-absorbed; Grass MATA MPL; Grass pollen modified allergen tyrosine-adsorbed; Pollinex Quattro; Pollinex Quattro Grass; Pollinex Quattro Tree; Pollinex Quattro® Birch; PQ Birch; PQ Grass; Tree MATA MPLLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Allergy Therapeutics
- Class Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Grass pollen hypersensitivity; Tree pollen hypersensitivity
- Phase III Allergic rhinoconjunctivitis
- Phase II/III Seasonal allergic rhinitis
Most Recent Events
- 01 Nov 2023 Allergy Therapeutics completes a phase-III clinical trials in Allergic rhinoconjunctivitis (Prevention) in the USA, Austria, Czechia, Germany, Hungary and Poland (SC) (EudraCT2019-001517-16) (NCT05540717)
- 11 Jun 2023 Efficacy data from a phase II/III trial in Grass pollen hypersensitivity released by Allergy Therapeutics
- 21 Jul 2022 Phase-III clinical trials in Allergic rhinoconjunctivitis (Prevention) in Hungary (SC) (EudraCT2019-001517-16) (NCT05540717)